MedPath

A study to examine whether treatment with prednisolone, given for 6 months for the first episode of nephrotic syndrome in children younger than 4 years isn more successful in keeping disease in control over one year than is therapy for 3 months

Phase 3
Conditions
Health Condition 1: null- First episode of idiopathic steroid sensitive nephrotic syndrome
Registration Number
CTRI/2015/06/005939
Lead Sponsor
Arvind Bagga
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
156
Inclusion Criteria

Patients with idiopathic, steroid sensitive, first episode of nephrotic syndrome, 1 to 4 years old, shall be included.

Exclusion Criteria

•Nephrotic syndrome known to be secondary to a systemic disorder, e.g., IgA nephropathy, systemic lupus erythematosus, Henoch Schonlein purpura, vasculitis, amyloidosis, hepatitis B antigenemia and Alport syndrome.

•Patients with impaired renal functions (serum creatinine >1.2 mg/dl, confirmed in 2 weeks)

•Patients who have received oral prednisolone, in the past for nephrotic syndrome

•Patients who have taken prednisolone in the past 4 weeks, in a dose more than 1 mg/kg for >10 days for any other reason

•Unclear treatment history

•Patients staying more than 100 km from the Institute or those not willing to come for clinic visits every two months

•Gross hematuria

•Patients with initial steroid resistance

•Patients who show relapse during the first 3 months of therapy (standard therapy)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion with relapse(s) during twelve monthsâ?? follow upTimepoint: During twelve months from randomization
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath